Skip to main content
Clinical Trials/NCT02682251
NCT02682251
Completed
Not Applicable

Engaging Patients in Heart Failure Management

Parkview Health1 site in 1 country10 target enrollmentFebruary 2016

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Congestive Heart Failure
Sponsor
Parkview Health
Enrollment
10
Locations
1
Primary Endpoint
Improved percentage of LV pacing
Status
Completed
Last Updated
6 years ago

Overview

Brief Summary

An interventional study to empower congestive heart failure patients who have a cardiac resynchronization therapy-cardiac implantable electronic device (CRT-CIED) by using a personal health record (PHR) to directly message them their device data and send alerts based on percent left ventricular pacing.

Detailed Description

An interventional study to empower congestive heart failure patients who have a cardiac resynchronization therapy-cardiac implantable electronic device (CRT-CIED) by using a personal health record (PHR) to directly message them their device data and send alerts based on percent left ventricular pacing. There will be three phases in this study. In the first phase the investigators will employ a user-centered design approach to better understand what types of information that patients who have a remotely monitored CRT-CIED would find beneficial towards understanding and managing their disease. The investigators also hope to uncover expectations for alert mechanisms and two-way messaging between provider and patient around CIED remote monitoring data. In the second phase the investigators will implement the PHR intervention as designed in phase 1. In the third phase of this study, the investigators will test the PHR intervention in a single arm, 6-month trial. A maximum of 120 participants (including patients and their caregiver, partner, and/or support persons) will be enrolled in the focus groups for phase 1. A maximum of 10 patients will be enrolled in the design session to follow in phase 1. After building the intervention in phase 2, a maximum of 30 patients will be enrolled in the technology trial for phase 3. Enrollment is projected to be complete within six months for phase 1, and within one year for phase 3. In phase 3, adult subjects (N=30) with a diagnosis of congestive heart failure undergoing chronic resynchronization therapy through their CIED will receive interventional messaging through their PHR regarding percent left ventricular pacing. The study duration will commence at the time of informed consent documentation during the first focus group and conclude at the time of the last patient visit during the technology trial. Impact of PHR messaging will be evaluated by timeliness of patient calls to clinic for adjustment in therapy, an improved percentage of LV pacing over 6 months compared to historical controls from the same clinic, as well as self-reported patient engagement. Timeliness of patient calls to clinic will be evaluated through record of patient calls to clinic 6 months prior to study and 6 months during study. Patient engagement will be evaluated through patient survey at start and end of study. Patients will follow standard of care + intervention during study.

Registry
clinicaltrials.gov
Start Date
February 2016
End Date
October 5, 2019
Last Updated
6 years ago
Study Type
Interventional
Study Design
Single Group
Sex
All

Investigators

Sponsor
Parkview Health
Responsible Party
Principal Investigator
Principal Investigator

Tammy Toscos

Research Scientist, Informatics

Parkview Health

Eligibility Criteria

Inclusion Criteria

  • Remotely monitored with CRT-CIED
  • focus groups 1 \& 2: implant ≤ 12 months
  • focus groups 3 \& 4: implant ≥ 12 months
  • Current patient of PPG-Cardiology
  • History of HFrEF (heart failure in the setting of reduced ejection fraction)
  • Access to computer and internet
  • \*Ability to provide informed consent
  • \*Age ≥ 18 years
  • 5 and 6 must apply to caregivers, partners, and/or support persons

Exclusion Criteria

  • Not remotely monitored with CRT-CIED
  • Not current patient of PPG-Cardiology
  • No history of HFrEF
  • Pacemaker dependent
  • Does not have access to computer and internet
  • \*Inability to provide informed consent
  • \*Age \< 18 years
  • \*Does not meet inclusion criteria
  • Only 6, 7, and 8 apply to caregivers, partners, and/or support persons
  • TECHNOLOGY TRIAL

Outcomes

Primary Outcomes

Improved percentage of LV pacing

Time Frame: 6 months during study

Timeliness of calls to clinic for adjustment in therapy

Time Frame: 6 months during study

Patient engagement evaluated through patient survey

Time Frame: 6 months during study

Study Sites (1)

Loading locations...

Similar Trials